Shares of Intrexon Corp. (NYSE:XON) have received a consensus recommendation of “Buy” from the eight ratings firms that are currently covering the company. Three investment analysts have rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating on the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $43.78.

Several research analysts have weighed in on the company. Griffin Securities reiterated a “buy” rating and set a $55.00 target price on shares of Intrexon Corp. in a report on Tuesday, August 16th. Zacks Investment Research downgraded Intrexon Corp. from a “buy” rating to a “hold” rating in a research note on Friday, August 12th. Vetr raised Intrexon Corp. from a “hold” rating to a “strong-buy” rating and set a $33.69 price target on the stock in a research note on Wednesday, August 3rd. Wunderlich reissued a “buy” rating and issued a $50.00 price target on shares of Intrexon Corp. in a research note on Thursday, July 7th. Finally, JMP Securities reissued a “buy” rating on shares of Intrexon Corp. in a research note on Sunday, July 17th.

In related news, SVP Nir Nimrodi bought 4,000 shares of the stock in a transaction that occurred on Monday, August 29th. The shares were acquired at an average price of $26.12 per share, with a total value of $104,480.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 55.10% of the stock is owned by corporate insiders.

Several hedge funds have recently added to or reduced their stakes in the stock. Legal & General Group Plc increased its stake in Intrexon Corp. by 3.4% in the first quarter. Legal & General Group Plc now owns 3,788 shares of the company’s stock worth $128,000 after buying an additional 126 shares in the last quarter. Public Employees Retirement Association of Colorado boosted its position in Intrexon Corp. by 1.8% in the second quarter. Public Employees Retirement Association of Colorado now owns 12,085 shares of the company’s stock worth $297,000 after buying an additional 209 shares during the last quarter. PNC Financial Services Group Inc. boosted its position in Intrexon Corp. by 1.7% in the second quarter. PNC Financial Services Group Inc. now owns 23,550 shares of the company’s stock worth $579,000 after buying an additional 400 shares during the last quarter. Metropolitan Life Insurance Co. NY boosted its position in Intrexon Corp. by 13.7% in the second quarter. Metropolitan Life Insurance Co. NY now owns 4,161 shares of the company’s stock worth $102,000 after buying an additional 501 shares during the last quarter. Finally, UBS Asset Management Americas Inc. boosted its position in Intrexon Corp. by 3.2% in the second quarter. UBS Asset Management Americas Inc. now owns 30,200 shares of the company’s stock worth $743,000 after buying an additional 940 shares during the last quarter. 84.05% of the stock is currently owned by institutional investors and hedge funds.

Shares of Intrexon Corp. (NYSE:XON) opened at 27.56 on Monday. The company’s 50-day moving average price is $27.31 and its 200 day moving average price is $27.92. The company’s market cap is $3.26 billion. Intrexon Corp. has a 52 week low of $18.52 and a 52 week high of $43.76.

Intrexon Corp. (NYSE:XON) last posted its earnings results on Tuesday, August 9th. The company reported ($0.42) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.26) by $0.16. The business had revenue of $52.50 million for the quarter, compared to the consensus estimate of $53.78 million. Intrexon Corp. had a negative return on equity of 19.00% and a negative net margin of 96.65%. The business’s revenue was up 17.0% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.37) earnings per share. On average, equities analysts forecast that Intrexon Corp. will post ($1.36) EPS for the current fiscal year.

Intrexon Corp. Company Profile

Intrexon Corporation (Intrexon) forms collaborations to create biologically based products and processes using synthetic biology. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components. The Company’s synthetic biology capabilities include the ability to control the amount, location and modification of biological molecules to control the function and output of living cells and optimize for desired results at an industrial scale.

5 Day Chart for NYSE:XON

Receive News & Stock Ratings for Intrexon Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon Corp. and related stocks with our FREE daily email newsletter.